2.57
price down icon16.83%   -0.52
after-market Handel nachbörslich: 2.60 0.03 +1.17%
loading
Schlusskurs vom Vortag:
$3.09
Offen:
$2.52
24-Stunden-Volumen:
31.21M
Relative Volume:
4.81
Marktkapitalisierung:
$518.17M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.2123
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-11.38%
1M Leistung:
+2.39%
6M Leistung:
+142.45%
1J Leistung:
+24.15%
1-Tages-Spanne:
Value
$2.30
$2.6599
1-Wochen-Bereich:
Value
$2.30
$3.42
52-Wochen-Spanne:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Firmenname
Esperion Therapeutics Inc
Name
Telefon
734-887-3903
Name
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Mitarbeiter
304
Name
Twitter
@esperioninc
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
ESPR's Discussions on Twitter

Vergleichen Sie ESPR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
2.57 623.01M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
143.49 63.27B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.67B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.04 39.27B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.21 23.02B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
448.93 20.66B 3.08B 1.24B 1.07B 25.61

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-18 Eingeleitet Goldman Neutral
2024-12-17 Eingeleitet Cantor Fitzgerald Overweight
2024-06-20 Herabstufung BofA Securities Neutral → Underperform
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-20 Fortgesetzt JP Morgan Neutral
2023-08-01 Hochstufung Northland Capital Under Perform → Market Perform
2023-06-15 Hochstufung BofA Securities Underperform → Buy
2023-03-16 Herabstufung BofA Securities Neutral → Underperform
2023-03-16 Herabstufung Northland Capital Market Perform → Under Perform
2023-03-07 Hochstufung Credit Suisse Underperform → Neutral
2023-02-27 Fortgesetzt BofA Securities Neutral
2023-02-24 Hochstufung Jefferies Hold → Buy
2023-02-03 Hochstufung Morgan Stanley Underweight → Equal-Weight
2022-08-03 Herabstufung Credit Suisse Neutral → Underperform
2022-05-05 Hochstufung JP Morgan Underweight → Neutral
2022-03-10 Eingeleitet H.C. Wainwright Buy
2021-10-19 Herabstufung Credit Suisse Outperform → Neutral
2021-10-14 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-05-05 Herabstufung Stifel Buy → Hold
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-03-11 Eingeleitet Morgan Stanley Equal-Weight
2021-02-12 Herabstufung Jefferies Buy → Hold
2021-02-09 Herabstufung Goldman Neutral → Sell
2021-01-15 Herabstufung BofA Securities Buy → Neutral
2020-11-10 Hochstufung Credit Suisse Neutral → Outperform
2020-09-29 Fortgesetzt JP Morgan Underweight
2020-08-11 Herabstufung Credit Suisse Outperform → Neutral
2020-04-01 Fortgesetzt BofA/Merrill Buy
2020-03-17 Hochstufung Citigroup Neutral → Buy
2020-02-24 Herabstufung Northland Capital Outperform → Market Perform
2020-02-14 Herabstufung Citigroup Buy → Neutral
2019-09-16 Hochstufung Goldman Sell → Neutral
2019-05-29 Herabstufung Goldman Neutral → Sell
2019-05-06 Hochstufung BofA/Merrill Underperform → Neutral
2019-04-26 Hochstufung Goldman Sell → Neutral
2019-03-13 Hochstufung JP Morgan Underweight → Neutral
2019-01-07 Bestätigt Needham Strong Buy
2018-12-13 Eingeleitet Goldman Sell
2018-10-29 Hochstufung Northland Capital Market Perform → Outperform
2018-10-16 Eingeleitet BTIG Research Buy
2018-08-17 Hochstufung Citigroup Neutral → Buy
2018-07-11 Herabstufung Northland Capital Outperform → Market Perform
2018-05-03 Herabstufung JP Morgan Neutral → Underweight
2018-05-02 Herabstufung BofA/Merrill Buy → Underperform
Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

pulisher
04:25 AM

Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade

04:25 AM
pulisher
11:58 AM

Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat

11:58 AM
pulisher
10:04 AM

Esperion Therapeutics’ Bold Move: Stock Offering at $2.50 - StocksToTrade

10:04 AM
pulisher
08:01 AM

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

08:01 AM
pulisher
07:10 AM

Esperion Therapeutics prices $75M public offering - MSN

07:10 AM
pulisher
04:49 AM

Why Is Esperion Therapeutics Stock Sinking Premarket Today? - Stocktwits

04:49 AM
pulisher
03:26 AM

Esperion Therapeutics Prices $75 Million Share Offering - MarketScreener

03:26 AM
pulisher
Oct 07, 2025

Esperion prices $75 million public offering of common stock By Investing.com - Investing.com Nigeria

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion prices public offering of 30 million shares at $2.50 each - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion Therapeutics Announces Pricing of $75 Million Public Offering of Common Stock - Quiver Quantitative

Oct 07, 2025
pulisher
Oct 07, 2025

$75M Raise — Esperion Prices 30M Shares to Fund Oral LDL‑C Program - Stock Titan

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion Announces Pricing of Public Offering of Common Stock - GlobeNewswire Inc.

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion Therapeutics Experiences Evaluation Revision Amidst Mixed Market Indicators and Performance Trends - Markets Mojo

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion announces proposed public offering of common stock - MarketScreener

Oct 07, 2025
pulisher
Oct 07, 2025

ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up - MSN

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion launches public offering of common stock to raise capital By Investing.com - Investing.com Australia

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion Therapeutics tumbles after stock offering launch - TradingView

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion Announces Strategic Expansion Plans for Bempedoic Acid - TipRanks

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion launches proposed public offering of common stock; shares fall 21% (ESPR:NASDAQ) - Seeking Alpha

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion stock tumbles after announcing public offering - Investing.com

Oct 07, 2025
pulisher
Oct 07, 2025

Esperion Announces Proposed Public Offering of Common Stock - Stock Titan

Oct 07, 2025
pulisher
Oct 06, 2025

Will Esperion Therapeutics Inc. outperform the marketMarket Activity Recap & Stepwise Entry and Exit Trade Signals - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Esperion Therapeutics Inc. rebound enough to break evenRate Hike & Low Risk Entry Point Tips - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL and NEXLIZET Prior to April 19, 2040 - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

Is Esperion Therapeutics Inc. stock a buy on dipsJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Esperion’s Share Surge Following Patent Lawsuit Settlement - StocksToTrade

Oct 05, 2025
pulisher
Oct 05, 2025

Esperion Therapeutics Gains Traction with Settlement and Strategic Moves - timothysykes.com

Oct 05, 2025
pulisher
Oct 05, 2025

Esperion’s Legal Victory Against Dr. Reddy’s Sparks Stock Surge - StocksToTrade

Oct 05, 2025
pulisher
Oct 05, 2025

Esperion Shares Surge Amid Patent Lawsuit Settlement - timothysykes.com

Oct 05, 2025
pulisher
Oct 05, 2025

Analyzing drawdowns of Esperion Therapeutics Inc. with statistical toolsPortfolio Update Summary & Stepwise Entry/Exit Trade Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Has Esperion Therapeutics Inc. found a price floorWeekly Market Summary & Weekly High Potential Stock Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Esperion Therapeutics Inc. stock attractive for hedge fundsOptions Play & Daily Profit Focused Stock Screening - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Esperion Therapeutics Inc. (0ET) stock see valuation expansion2025 Earnings Impact & Fast Gaining Stock Reports - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockAnalyst Downgrade & Free Long-Term Investment Growth Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

What does recent volatility data suggest for Esperion Therapeutics Inc.July 2025 Drop Watch & Reliable Price Breakout Alerts - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Esperion Therapeutics, Inc. (ESPR) and Lead Plaintiff Deadline: March 14, 2016 - ACCESS Newswire

Oct 04, 2025
pulisher
Oct 04, 2025

Esperion Therapeutics Surges on Patent Settlement With Dr. Reddy’s - StocksToTrade

Oct 04, 2025
pulisher
Oct 04, 2025

Esperion Shares Soar Amid Resolving Patent Dispute - timothysykes.com

Oct 04, 2025
pulisher
Oct 03, 2025

Is Esperion Therapeutics Inc a good long term investmentEquity Performance Review & In-Depth Analyst Ratings Explained Simply - earlytimes.in

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion settles patent litigation with Dr. Reddy’s Laboratories By Investing.com - Investing.com Nigeria

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpTime to Buy? - MarketBeat

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. - GlobeNewswire

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs - Seeking Alpha

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug - MarketScreener

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion settles patent litigation with Dr. Reddy’s Laboratories - Investing.com

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion Announces Settlement Agreement with Dr. Reddy’s Laboratories Regarding NEXLETOL and NEXLIZET Patent Litigation - Quiver Quantitative

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion reaches settlement agreement with ANDA filer - MarketScreener

Oct 03, 2025
pulisher
Oct 03, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 | Dow Theory Letters - FinancialContent

Oct 03, 2025

Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Esperion Therapeutics Inc-Aktie (ESPR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Koenig Sheldon L.
President and CEO
Sep 17 '25
Sale
2.79
28,427
79,254
1,518,831
Halladay Benjamin
Chief Financial Officer
Sep 17 '25
Sale
2.81
7,046
19,785
474,862
$20.34
price down icon 0.54%
$9.97
price down icon 1.68%
drug_manufacturers_specialty_generic RDY
$13.99
price down icon 0.29%
$58.17
price up icon 0.35%
$139.08
price up icon 1.52%
$448.93
price down icon 1.73%
Kapitalisierung:     |  Volumen (24h):